This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled single (SAD)
and multiple ascending (MAD) ascending dose study to assess the safety, tolerability, and
pharmacokinetics (PK) of IGM-6268 administered intranasally and intraorally in healthy
volunteers. IGM-6268 or placebo will be administered by intranasal + intraoral spray using a
Teleflex Mucosal Atomization Device Nasal™ Intranasal Mucosal Atomization Device once (SAD),
or once or twice each day for 5 days (MAD).